Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Medline Inc. · 10-Q · Q2 FY2026 · Period ended Jun 27, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

There has been no material change in our exposure to market risks as disclosed in the 2025 Form 10-K.